Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin
Evaluation of the Effectiveness, Safety, and Tolerability of Tapentadol PR Versus a Combination of Tapentadol PR and Pregabalin in Subjects With Severe Chronic Low Back Pain With a Neuropathic Pain Component
Sponsor: Grünenthal GmbH
Listed as NCT01352741, this PHASE4 trial focuses on Low Back Pain and Neuropathic Pain and remains completed. Sponsored by Grünenthal GmbH, it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Nov 2019 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Grünenthal GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Alicante, Spain , Amsterdam, Netherlands , Badalona, Spain , Barcelona, Spain , Berlin, Germany , Bydgoszcz, Poland , Böhlen, Germany , Centelles, Spain , Cologne, Germany and 38 more locations